Iovance Biotherapeutics Faces Governance Scrutiny and Equity Raise Plan Amid Amtagvi Commercial Traction Questions

Iovance Biotherapeutics is down 14.9% after a shareholder investigation over past disclosure issues and a reaffirmation of its 2025 revenue guidance. Management is opting to fund growth through ongoing equity issuance, highlighting tension between internal expectations and market skepticism. The company's investment narrative and risk-reward profile are affected by governance scrutiny, commercial traction, and potential setbacks in demand, reimbursement, or international approvals.